Hybrid phage and mammalian display technology enabling highly selective and functionally optimized CAR, TCR, and bispecific engager discovery. Designed to produce candidates with improved pharmaceutical quality, minimal off-target toxicity, and reduced immunogenic risk through fully human antibody fragments. Applied to iNKT cell engineering for oncology and immune-mediated diseases.

Biotech Distilled coverage (1)

2026-06-13 MiNK Therapeutics (INKT) - Scientific Deep Dive for agenT-797 and the iNKT Cell Pipeline

Articles open on Substack. Some deep dives are subscriber-only.